Literature DB >> 9267996

Studies of the genetic variability of the coding region of the hepatocyte nuclear factor-4alpha in Caucasians with maturity onset NIDDM.

A M Møller1, S A Urhammer, L T Dalgaard, R Reneland, L Berglund, T Hansen, J O Clausen, H Lithell, O Pedersen.   

Abstract

Mutations in the hepatocyte nuclear factor-4alpha (HNF-4alpha) gene cause the type 1 form of maturity onset diabetes of the young (MODY1). To address the question of whether genetic variability of HNF-4alpha is associated with late onset non-insulin-dependent diabetes mellitus (NIDDM) we have sequenced the coding region and intron/exon boundaries of the gene in 36 randomly recruited Danish NIDDM patients. Two nucleotide substitutions that changed the sequence of HNF-4alpha were identified: Thr/Ile130, which has been reported previously and a novel Val/Met255. The Val/Met 255 mutation was found in 4 of 477 Danish NIDDM patients and in none of 217 glucose tolerant control subjects; thus it cannot be excluded that this mutation may have an impact on NIDDM susceptibility. Among 509 NIDDM patients the allelic frequency of the Thr/Ile130 variant was 4.7% (95% confidence interval: 3.4-6.0%) compared to 1.9% (0.7-3.1%) among 239 control subjects (p = 0.008). However, in a population sample of 942 Swedish men with an average age of 70 years the allelic frequency of the variant was similar in 246 men with either impaired glucose tolerance (5.6% [2.6-8.6%]) or NIDDM (5.4% [2.7-8.1%]) as compared to 666 glucose tolerant men (5.1% [3.9-6.3%]). Also in a population sample of 369 young healthy Danes the prevalence of the codon 130 variant (4.7% [3.2-6.2%]) was similar to what was found in Swedish Caucasians. Thus, the allelic frequency of the Thr/Ile130 variant among the control subjects in the Danish case-control study deviates from the prevalence in the two other studies which is why we consider the significant association between the codon 130 variant and NIDDM an incidental finding. In glucose tolerant subjects the codon 130 variant in its heterozygous form had no major effect on glucose-induced insulin and C-peptide release although a tendency to a lower insulin secretion during an oral glucose tolerance test was seen in middle-aged subjects. In conclusion, variability in the coding region of the HNF-4alpha gene is not a common cause of NIDDM among whites of Danish ancestry. However, a Val/Met255 mutation was found exclusively in NIDDM patients (0.8% of cases) and functional as well as family segregation studies are needed to determine whether this HNF-4alpha variant is a NIDDM causing mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267996     DOI: 10.1007/s001250050778

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  16 in total

1.  Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1.

Authors:  F M Sladek; M D Ruse; L Nepomuceno; S M Huang; M R Stallcup
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

Review 2.  Molecular etiologies of MODY and other early-onset forms of diabetes.

Authors:  David Q Shih; Markus Stoffel
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

3.  Susceptibility background for type 2 diabetes in eleven Mexican Indigenous populations: HNF4A gene analysis.

Authors:  M A Granados-Silvestre; M G Ortiz-López; J Granados; S Canizales-Quinteros; Rosenda I Peñaloza-Espinosa; C Lechuga; V Acuña-Alonzo; K Sánchez-Pozos; M Menjivar
Journal:  Mol Genet Genomics       Date:  2017-07-07       Impact factor: 3.291

4.  Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha.

Authors:  S Pruhova; J Ek; J Lebl; Z Sumnik; F Saudek; M Andel; O Pedersen; T Hansen
Journal:  Diabetologia       Date:  2003-01-08       Impact factor: 10.122

Review 5.  The role of HNF4A variants in the risk of type 2 diabetes.

Authors:  Karen L Mohlke; Michael Boehnke
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

6.  Variation near the hepatocyte nuclear factor (HNF)-4alpha gene associates with type 2 diabetes in the Danish population.

Authors:  S K Hansen; C S Rose; C Glümer; T Drivsholm; K Borch-Johnsen; T Jørgensen; O Pedersen; T Hansen
Journal:  Diabetologia       Date:  2005-02-25       Impact factor: 10.122

7.  Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs.

Authors:  S Ghosh; R M Watanabe; E R Hauser; T Valle; V L Magnuson; M R Erdos; C D Langefeld; J Balow; D S Ally; K Kohtamaki; P Chines; G Birznieks; H S Kaleta; A Musick; C Te; J Tannenbaum; W Eldridge; S Shapiro; C Martin; A Witt; A So; J Chang; B Shurtleff; R Porter; K Kudelko; A Unni; L Segal; R Sharaf; J Blaschak-Harvan; J Eriksson; T Tenkula; G Vidgren; C Ehnholm; E Tuomilehto-Wolf; W Hagopian; T A Buchanan; J Tuomilehto; R N Bergman; F S Collins; M Boehnke
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

8.  T130I mutation in HNF-4alpha gene is a loss-of-function mutation in hepatocytes and is associated with late-onset Type 2 diabetes mellitus in Japanese subjects.

Authors:  Q Zhu; K Yamagata; A Miura; N Shihara; Y Horikawa; J Takeda; J Miyagawa; Y Matsuzawa
Journal:  Diabetologia       Date:  2003-03-25       Impact factor: 10.122

9.  Genetic evidence that HNF-1alpha-dependent transcriptional control of HNF-4alpha is essential for human pancreatic beta cell function.

Authors:  Sara K Hansen; Marcelina Párrizas; Maria L Jensen; Stepanka Pruhova; Jakob Ek; Sylvia F Boj; Anders Johansen; Miguel A Maestro; Francisca Rivera; Hans Eiberg; Michal Andel; Jan Lebl; Oluf Pedersen; Jorge Ferrer; Torben Hansen
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

10.  Identification of an endogenous ligand bound to a native orphan nuclear receptor.

Authors:  Xiaohui Yuan; Tuong Chi Ta; Min Lin; Jane R Evans; Yinchen Dong; Eugene Bolotin; Mark A Sherman; Barry M Forman; Frances M Sladek
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.